Linked Data API

Show Search Form

Search Results

1140170
registered interest false more like this
date less than 2019-07-18more like thismore than 2019-07-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Heart Diseases and Strokes: Females more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will respond to the recommendations in the report entitled Call for Action: Inquiry into heart attack and stroke, published by the all-party Parliamentary group on women’s health in July 2019; and if he will make a statement. more like this
tabling member constituency Dewsbury more like this
tabling member printed
Paula Sherriff more like this
uin 279083 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>NHS England has acknowledged the recently published report and will be considering the content.</p><p>Improving the prevention and treatment of heart attacks and stroke are key aims in the NHS Long Term Plan, with an important milestone being for the National Health Service to help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years. The NHS Long Term Plan highlights that outcomes from heart attack and stroke can be improved, and that there should be a focus on inequalities.</p><p><strong> </strong></p><p><strong> </strong></p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-23T16:54:04.3Zmore like thismore than 2019-07-23T16:54:04.3Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4426
label Biography information for Paula Sherriff more like this
1140408
registered interest false more like this
date less than 2019-07-18more like thismore than 2019-07-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Synacthen: Prices more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether his Department is aware that synacthen has recently increased in cost from £2.70 per vial to £38 per vial; and if he will make a statement. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 279027 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>The Department agreed the list price increase for Synacthen in March 2015.</p><p>The previous Pharmaceutical Price Regulation Scheme, the current 2019 Voluntary Scheme for Branded Medicines Pricing and Access and our statutory branded medicines pricing scheme all have detailed arrangements for how companies can request an increase to the National Health Service list price for a product.</p><p>Companies must comply with the rules of the relevant scheme when making a price increase request and all price increase requests must receive Departmental approval before they can take effect.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-23T16:53:15.603Zmore like thismore than 2019-07-23T16:53:15.603Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
1140227
registered interest false more like this
date less than 2019-07-18more like thismore than 2019-07-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading 5G: Health Hazards more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what research his Department has conducted on the potential effect on public health of upgrading infrastructure to support 5G. more like this
tabling member constituency Streatham more like this
tabling member printed
Chuka Umunna more like this
uin 279011 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>Public Health England (PHE) advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The ICNIRP guidelines cover exposures arising from new 5G base stations, as well as from older technologies.</p><p>Many exposure measurements have been made at publicly accessible locations near to mobile phone base stations, and these have consistently been well within guidelines. It is possible that there may be a small increase in overall exposure to radio waves when 5G is added to an existing network or in a new area; however, the overall exposure is expected to remain low relative to guidelines and as such there should be no consequences for public health.</p><p> </p><p>PHE has published information about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p> </p><p>PHE continues to monitor the health-related evidence applicable to radio waves and is committed to updating its advice as required.</p><p><strong> </strong></p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-23T16:52:28.177Zmore like thismore than 2019-07-23T16:52:28.177Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4128
label Biography information for Chuka Umunna more like this
1139295
registered interest false more like this
date less than 2019-07-16more like thismore than 2019-07-16
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Calea: Parenteral Nutrition more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking with Calea UK Limited to ensure that (a) outpatients and (b) inpatients who are reliant on total parenteral nutrition are able to access the supplies and equipment they need. more like this
tabling member constituency Wansbeck more like this
tabling member printed
Ian Lavery more like this
uin 277742 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>We are aware that there is currently disruption affecting the supply of parenteral nutrition from the supplier Calea. This is due to necessary changes in their manufacturing process, meaning that Calea is operating at reduced capacity. We understand the concerns of those who use these products. We are working closely with the Medicines and Healthcare products Regulatory Agency, NHS England and NHS Improvement, the supplier and national experts to resolve this supply issue as quickly as possible to ensure patients requiring parenteral nutrition can be maintained on treatment.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-23T16:51:36.5Zmore like thismore than 2019-07-23T16:51:36.5Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4139
label Biography information for Ian Lavery more like this
1139370
registered interest false more like this
date less than 2019-07-16more like thismore than 2019-07-16
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the closure of the Commissioning Support Programme on treatments within NHS England’s Clinical Commissioning Policy programme; and if he will make a statement. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 277725 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>NHS England does not believe that the closure of the Commissioning Support Programme will leave a gap in the review of treatments.</p><p>The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme, undertaken by the National Institute for Health and Care Excellence (NICE), except where there is a clear rationale not to do so. NICE expects to implement this expansion from April 2020. It will be in a position to start progressing topics through the NICE topic selection process from the summer of 2019.</p><p>All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage as for all topics, post stakeholder testing. These are now being progressed though the usual development process. This process is set out in ‘Methods: National Clinical Policies’ at the following link:</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/" target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p><p>The voluntary scheme agreed between Department and the Association of the British Pharmaceutical Industry on getting the best value and most effective medicines into use more quickly for branded medicines pricing and access was published in November 2018. The voluntary scheme started on 1 January 2019 and will be in place for five years until 2023.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN 277724 more like this
question first answered
less than 2019-07-23T16:50:58.65Zmore like thismore than 2019-07-23T16:50:58.65Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1139369
registered interest false more like this
date less than 2019-07-16more like thismore than 2019-07-16
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 April 2019 to Question 236381, what steps NHS England has taken to fill the gap left by the closure of the Commissioning Support Programme for those treatments that are awaiting review by the Clinical Priorities Advisory Group. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 277724 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>NHS England does not believe that the closure of the Commissioning Support Programme will leave a gap in the review of treatments.</p><p>The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme, undertaken by the National Institute for Health and Care Excellence (NICE), except where there is a clear rationale not to do so. NICE expects to implement this expansion from April 2020. It will be in a position to start progressing topics through the NICE topic selection process from the summer of 2019.</p><p>All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage as for all topics, post stakeholder testing. These are now being progressed though the usual development process. This process is set out in ‘Methods: National Clinical Policies’ at the following link:</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/" target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p><p>The voluntary scheme agreed between Department and the Association of the British Pharmaceutical Industry on getting the best value and most effective medicines into use more quickly for branded medicines pricing and access was published in November 2018. The voluntary scheme started on 1 January 2019 and will be in place for five years until 2023.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN 277725 more like this
question first answered
less than 2019-07-23T16:50:58.587Zmore like thismore than 2019-07-23T16:50:58.587Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1140335
registered interest false more like this
date less than 2019-07-18more like thismore than 2019-07-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Rehabilitation Centres: Finance more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will increase the (a) funding for and (b) provision of residential drug treatment services. more like this
tabling member constituency Easington more like this
tabling member printed
Grahame Morris more like this
uin 278960 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>The Government provides funding to local authorities for their public health responsibilities through a public health grant. It is for individual local authorities to decide their spending priorities based on an assessment of local need, including the need for residential drug treatment services taking account of their statutory duties.</p><p>Future funding for local authority public health functions will be a matter for the Spending Review.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN 278956 more like this
question first answered
less than 2019-07-23T16:50:57.143Zmore like thismore than 2019-07-23T16:50:57.143Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
3973
label Biography information for Grahame Morris more like this
1140302
registered interest false more like this
date less than 2019-07-18more like thismore than 2019-07-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Rehabilitation Centres: County Durham more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of residential drug recovery services for women in County Durham. more like this
tabling member constituency Easington more like this
tabling member printed
Grahame Morris more like this
uin 278956 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>The Government provides funding to local authorities for their public health responsibilities through a public health grant. It is for individual local authorities to decide their spending priorities based on an assessment of local need, including the need for residential drug treatment services taking account of their statutory duties.</p><p>Future funding for local authority public health functions will be a matter for the Spending Review.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN 278960 more like this
question first answered
less than 2019-07-23T16:50:57.097Zmore like thismore than 2019-07-23T16:50:57.097Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
3973
label Biography information for Grahame Morris more like this
1140210
registered interest false more like this
date less than 2019-07-18more like thismore than 2019-07-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cystic Fibrosis: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will set a deadline for NHS England and Vertex Pharmaceuticals to come to an agreement to enable access to cystic fibrosis medicines produced by that company. more like this
tabling member constituency Bristol East more like this
tabling member printed
Kerry McCarthy more like this
uin 278929 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN 278928 more like this
question first answered
less than 2019-07-23T16:49:59.517Zmore like thismore than 2019-07-23T16:49:59.517Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
1491
label Biography information for Kerry McCarthy more like this
1140209
registered interest false more like this
date less than 2019-07-18more like thismore than 2019-07-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cystic Fibrosis: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent discussions there have been between Vertex Pharmaceuticals and NHS England with on cystic fibrosis medicines. more like this
tabling member constituency Bristol East more like this
tabling member printed
Kerry McCarthy more like this
uin 278928 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-23more like thismore than 2019-07-23
answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN 278929 more like this
question first answered
less than 2019-07-23T16:49:59.47Zmore like thismore than 2019-07-23T16:49:59.47Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
1491
label Biography information for Kerry McCarthy more like this